Oral Immunotherapy With Human Secretory Immunoglobulin A Improves Survival in the Hamster Model of Clostridioides difficile Infection.

Fahad Shahid

• 1 min read

JOURNAL
The Journal of infectious diseases

DOI
10.1093/infdis/jiab087

Author(s)
EF Chiari;W Weiss;MR Simon;ST Kiessig;M Pulse;SC Brown;HR Gerding;M Mandago;K Gisch;C von Eichel-Streiber

Abstract
Coadministration of human secretory IgA (sIgA) together with subtherapeutic vancomycin enhanced survival in the Clostridioides difficile infection (CDI) hamster model. Vancomycin (5 or 10 mg/kg × 5 days) plus healthy donor plasma sIgA/monomeric IgA (TID × 21 days) or hyperimmune sIgA/monomeric IgA (BID × 13 days) enhanced survival. Survival was improved compared to vancomycin alone, P = .018 and .039 by log-rank Mantel-Cox, for healthy and hyperimmune sIgA, respectively. Passive immunization with sIgA (recombinant human secretory component plus IgA dimer/polymer from pooled human plasma) can be administered orally and prevents death in a partially treated CDI hamster model.

Sign up for more like this.

Enter your email
Subscribe